Herbal Medicine for Colorectal Cancer Treatment: Molecular Mechanisms and Clinical Applications

Abstract

Colorectal cancer (CRC) is one of the most common malignant tumours and is the second leading cause of cancer-related mortality worldwide. Despite the availability of preventative, diagnostic and treatment methods including endoscopic treatment, surgical intervention, radiotherapy, biologics, salvage therapy and immunotherapy, the mortality rate associated with CRC remains alarming. Consequently, there is a pressing need to search for medicines for the treatment of CRC. Phytomedicines have been shown to suppress the proliferation and metastasis of CRC through various mechanisms, including immune regulation, modulation of gut microbiota, targeting of stem cells, macrophage polarisation, glycolysis, ferroptosis induction, modulation of extracellular vesicles, activation of mitochondria-induced apoptosis, inflammation reduction, oxidative stress management and intervention of autophagy. Furthermore, numerous studies have reported the anti-cancer and anti-metastatic effects of various phytomedicines, including curcumin, resveratrol, berberine, shikonin, dihydroartemisinin, fucoidan, luteolin, andrographolide, piperine, kaempferol, emodin, cannabidiol, tanshinone IIA and evodiamine. In this review, we sort out the effects and mechanisms of phytomedicines on CRC and outline the major phytomedicines commonly used in CRC treatment. We hope that these phytomedicines may serve as promising drugs or important lead compounds for the management of CRC.

Keywords

colorectal cancer / herbal medicine / molecular mechanisms

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229-263.

[2] S. G. Patel, J. J. Karlitz, T. Yen, C. H. Lieu, and C. R. Boland, “The Rising Tide of Early-Onset Colorectal Cancer: A Comprehensive Review of Epidemiology, Clinical Features, Biology, Risk Factors, Prevention, and Early Detection,” Lancet Gastroenterology & Hepatology 7, no. 3 (2022): 262-274.

[3] Q. Wang, X. Shen, G. Chen, and J. Du, “Drug Resistance in Colorectal Cancer: From Mechanism to Clinic,” Cancers (Basel) 14, no. 12 (2022): 2928.

[4] R. Abedizadeh, F. Majidi, H. R. Khorasani, H. Abedi, and D. Sabour, “Colorectal Cancer: A Comprehensive Review of Carcinogenesis, Diagnosis, and Novel Strategies for Classified Treatments,” Cancer Metastasis Reviews 43, no. 2 (2024): 729-753.

[5] E. Dekker, P. J. Tanis, J. L. A. Vleugels, P. M. Kasi, and M. B. Wallace, “Colorectal Cancer,” Lancet 394, no. 10207 (2019): 1467-1480.

[6] M. Al Zein, M. Boukhdoud, H. Shammaa, et al., “Immunotherapy and Immunoevasion of Colorectal Cancer,” Drug Discovery Today 28, no. 9 (2023): 103669.

[7] J. F. Chen, S. W. Wu, Z. M. Shi, and B. Hu, “Traditional Chinese Medicine for Colorectal Cancer Treatment: Potential Targets and Mechanisms of Action,” Chinese Medicine 18, no. 1 (2023): 14.

[8] D. S. M. Chatzileontiadou, H. Sloane, A. T. Nguyen, S. Gras, and E. J. Grant, “The Many Faces of CD4(+) T Cells: Immunological and Structural Characteristics,” International Journal of Molecular Sciences 22, no. 1 (2020): 1-27.

[9] B. J. Laidlaw, J. E. Craft, and S. M. Kaech, “The Multifaceted Role of CD4+ T Cells in CD8+ T Cell Memory,” Nature Reviews. Immunology 16, no. 2 (2016): 102-111.

[10] Z. H. Lu, Y. Ding, Y. J. Wang, et al., “Early Administration of Wumei Wan Inhibit Myeloid-Derived Suppressor Cells via PI3K/Akt Pathway and Amino Acids Metabolism to Prevent Colitis-Associated Colorectal Cancer,” Journal of Ethnopharmacology 333 (2024): 118260.

[11] Y. Kimura and M. Sumiyoshi, “Two Hydroxyflavanones Isolated From Scutellaria Baicalensis Roots Prevent Colitis-Associated Colon Cancer in C57BL/6 J Mice by Inhibiting Programmed Cell Death-1, Interleukin 10, and Thymocyte Selection-Associated High Mobility Group Box Proteins TOX/TOX2,” Phytomedicine 100 (2022): 154076.

[12] Z. Pan, X. Xie, Y. Chen, et al., “Huang Qin Decoction Inhibits the Initiation of Experimental Colitis Associated Carcinogenesis by Controlling the PAD4 Dependent NETs,” Phytomedicine 107 (2022): 154454.

[13] M. S. Carlino, J. Larkin, and G. V. Long, “Immune Checkpoint Inhibitors in Melanoma,” Lancet 398, no. 10304 (2021): 1002-1014.

[14] E. J. Lee, Y. S. Kim, J. H. Kim, et al., “Uncovering the Colorectal Cancer Immunotherapeutic Potential: Evening Primrose (Oenothera biennis) Root Extract and Its Active Compound Oenothein B Targeting the PD-1/PD-L1 Blockade,” Phytomedicine 125 (2024): 155370.

[15] B. Yi, S. Zhang, S. Yan, et al., “Marsdenia Tenacissima Enhances Immune Response of Tumor Infiltrating T Lymphocytes to Colorectal Cancer,” Frontiers in Immunology 14 (2023): 1238694.

[16] G. Wang, Y. Z. Wang, Y. Yu, P. H. Yin, K. Xu, and H. Zhang, “The Anti-Tumor Effect and Mechanism of Triterpenoids in Rhus chinensis Mill. On Reversing Effector CD8+ T-Cells Dysfunction by Targeting Glycolysis Pathways in Colorectal Cancer,” Integrative Cancer Therapies 20 (2021): 15347354211017219.

[17] C. Liu, M. Xu, L. Yan, et al., “Honeysuckle-Derived MicroRNA2911 Inhibits Tumor Growth by Targeting TGF-β1,” Chinese Medicine 16, no. 1 (2021): 49.

[18] H. Yang, G. G. Yue, K. K. Yuen, et al., “Mechanistic Insights Into the Anti-Tumor and Anti-Metastatic Effects of Patrinia villosa Aqueous Extract in Colon Cancer via Modulation of TGF-β R1-smad2/3-E-Cadherin and FAK-RhoA-Cofilin Pathways,” Phytomedicine 117 (2023): 154900, https://doi.org/10.1016/j.phymed.2023.154900.

[19] F. Yuan, W. Wu, L. Ma, et al., “Turmeric and Curcuminiods Ameliorate Disorders of Glycometabolism Among Subjects With Metabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,” Pharmacological Research 177 (2022): 106121.

[20] M. Li, G. G. Yue, S. K. Tsui, K. P. Fung, and C. B. Lau, “Turmeric Extract, With Absorbable Curcumin, has Potent Anti-Metastatic Effect In Vitro and In Vivo,” Phytomedicine 46 (2018): 131-141.

[21] J. Lv, Y. Jia, J. Li, et al., “Gegen Qinlian Decoction Enhances the Effect of PD-1 Blockade in Colorectal Cancer With Microsatellite Stability by Remodelling the Gut Microbiota and the Tumour Microenvironment,” Cell Death & Disease 10, no. 6 (2019): 415.

[22] C. Guo, Z. You, H. Shi, et al., “SLC38A2 and Glutamine Signalling in cDC1s Dictate Anti-Tumour Immunity,” Nature 620, no. 7972 (2023): 200-208.

[23] I. Heras-Murillo, I. Adán-Barrientos, M. Galán, S. K. Wculek, and D. Sancho, “Dendritic Cells as Orchestrators of Anticancer Immunity and Immunotherapy,” Nature Reviews. Clinical Oncology 21, no. 4 (2024): 257-277.

[24] M. J. Pittet, M. di Pilato, C. Garris, and T. R. Mempel, “Dendritic Cells as Shepherds of T Cell Immunity in Cancer,” Immunity 56, no. 10 (2023): 2218-2230.

[25] L. Hato, A. Vizcay, I. Eguren, et al., “Dendritic Cells in Cancer Immunology and Immunotherapy,” Cancers (Basel) 16, no. 5 (2024): 981.

[26] H. Ma, W. Fang, Q. Li, Y. Wang, and S. X. Hou, “Arf1 Ablation in Colorectal Cancer Cells Activates a Super Signal Complex in DC to Enhance Anti-Tumor Immunity,” Advanced Science 10, no. 32 (2023): e2305089.

[27] Q. Mao, J. Min, R. Zeng, et al., “Self-Assembled Traditional Chinese Nanomedicine Modulating Tumor Immunosuppressive Microenvironment for Colorectal Cancer Immunotherapy,” Theranostics 12, no. 14 (2022): 6088-6105.

[28] S. Deng, G. Zhang, J. Kuai, et al., “Lentinan Inhibits Tumor Angiogenesis via Interferon γ and in a T Cell Independent Manner,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 260.

[29] X. Kong, C. Liu, P. Lu, et al., “Combination of UPLC-Q-TOF/MS and Network Pharmacology to Reveal the Mechanism of Qizhen Decoction in the Treatment of Colon Cancer,” ACS Omega 6, no. 22 (2021): 14341-14360.

[30] X. Kong, Q. Li, D. Wang, M. Wang, F. Yang, and J. Meng, “Mechanism of Qizhen Decoction-Mediated Maturation of DC Cells to Activate the IL-12/JAK2/STAT4 Pathway to Sensitise PD-1 Inhibitors in the Treatment of Colorectal Cancer,” Journal of Ethnopharmacology 320 (2024): 117399.

[31] Y. Jiang, Y. Hu, Y. Yang, et al., “Tong-Xie-Yao-Fang Promotes Dendritic Cells Maturation and Retards Tumor Growth in Colorectal Cancer Mice With Chronic Restraint Stress,” Journal of Ethnopharmacology 319, no. Pt 1 (2024): 117069.

[32] C. Wan, Q. Ma, S. Anderson, et al., “Effects of Curcuminoids and Surfactant-Formulated Curcumin on Chemo-Resistant Colorectal Cancer,” American Journal of Chinese Medicine 51, no. 6 (2023): 1577-1594, https://doi.org/10.1142/S0192415X23500714.

[33] Z. Lin, L. Chen, M. Cheng, et al., “Cortex Periplocae Modulates the Gut Microbiota to Restrict Colitis and Colitis-Associated Colorectal Cancer via Suppression of Pathogenic Th17 Cells,” Biomedicine & Pharmacotherapy 153 (2022): 113399.

[34] C. Z. Wang, C. Wan, Y. Luo, et al., “Ginseng Berry Concentrate Prevents Colon Cancer via Cell Cycle, Apoptosis Regulation, and Inflammation-Linked Th17 Cell Differentiation,” Journal of Physiology and Pharmacology 72, no. 2 (2021): 225-237.

[35] C. Z. Wang, C. Wan, Y. Luo, et al., “Effects of Dihydroartemisinin, a Metabolite of Artemisinin, on Colon Cancer Chemoprevention and Adaptive Immune Regulation,” Molecular Biology Reports 49, no. 4 (2022): 2695-2709.

[36] E. Giner, M. C. Recio, J. L. Ríos, J. M. Cerdá-Nicolás, and R. M. Giner, “Chemopreventive Effect of Oleuropein in Colitis-Associated Colorectal Cancer in c57bl/6 Mice,” Molecular Nutrition & Food Research 60, no. 2 (2016): 242-255.

[37] H. Sui, W. Deng, Q. Chai, et al., “YTE-17 Inhibits Colonic Carcinogenesis by Resetting Antitumor Immune Response via Wnt5a/JNK Mediated Metabolic Signaling,” Journal of Pharmaceutical Analysis 14, no. 4 (2024): 100901.

[38] H. Nishikawa and S. Koyama, “Mechanisms of Regulatory T Cell Infiltration in Tumors: Implications for Innovative Immune Precision Therapies,” Journal for Immunotherapy of Cancer 9, no. 7 (2021): e002591, https://doi.org/10.1136/jitc-2021-002591.

[39] W. Fong, Q. Li, F. Ji, et al., “Lactobacillus gallinarum-Derived Metabolites Boost Anti-PD1 Efficacy in Colorectal Cancer by Inhibiting Regulatory T Cells Through Modulating IDO1/Kyn/AHR Axis,” Gut 72, no. 12 (2023): 2272-2285.

[40] Z. Liu, N. Zheng, J. Li, et al., “N6-Methyladenosine-Modified Circular RNA QSOX1 Promotes Colorectal Cancer Resistance to Anti-CTLA-4 Therapy Through Induction of Intratumoral Regulatory T Cells,” Drug Resistance Updates 65 (2022): 100886.

[41] H. Sui, L. Zhang, K. Gu, et al., “YYFZBJS Ameliorates Colorectal Cancer Progression in Apc (Min/+) Mice by Remodeling Gut Microbiota and Inhibiting Regulatory T-Cell Generation,” Cell Communication and Signaling 18, no. 1 (2020): 113.

[42] Y. Zhang, N. Chai, Z. Wei, et al., “YYFZBJS Inhibits Colorectal Tumorigenesis by Enhancing Tregs-Induced Immunosuppression Through HIF-1α Mediated Hypoxia In Vivo and In Vitro,” Phytomedicine 98 (2022): 153917.

[43] D. Chen, Y. Yang, and P. Yang, “Quxie Capsule Inhibits Colon Tumor Growth Partially Through Foxo1-Mediated Apoptosis and Immune Modulation,” Integrative Cancer Therapies 18 (2019): 1534735419846377.

[44] C. A. Geng, F. Y. Chen, J. B. Zheng, et al., “Rubiginosin B Selectively Inhibits Treg Cell Differentiation and Enhances Anti-Tumor Immune Responses by Targeting Calcineurin-NFAT Signaling Pathway,” Phytomedicine 116 (2023): 154898.

[45] C. C. Wong and J. Yu, “Gut Microbiota in Colorectal Cancer Development and Therapy,” Nature Reviews. Clinical Oncology 20, no. 7 (2023): 429-452.

[46] F. Karam, Y. El Deghel, R. Iratni, A. H. Dakroub, and A. H. Eid, “The Gut Microbiome and Colorectal Cancer: An Integrative Review of the Underlying Mechanisms,” Cell Biochemistry and Biophysics (2025).

[47] Y. Xiong, X. Zheng, Y. Xie, Y. Gong, and Y. I. Luo, “Effect of Cyasterone on Intestinal Flora in a (BRAF)V600E-Mutant Mouse Model of Colorectal Cancer,” Die Pharmazie 77, no. 10 (2022): 291-294.

[48] J. J. Zhu, H. Y. Liu, L. J. Yang, et al., “Anti-Tumour Effect of Huangqin Decoction on Colorectal Cancer Mice Through Microbial Butyrate Mediated PI3K/Akt Pathway Suppression,” Journal of Medical Microbiology 72, no. 5 (2023): 1-13.

[49] Y. Liu, Q. Zhang, L. Lu, et al., “Huang-Qin Decoction Alleviates Deoxycholic Acid-Induced Colorectal Cancer in Mice by Regulating Gut Microbiota,” Journal of Ethnopharmacology 346 (2025): 119715.

[50] Z. Zhang, S. Shao, Y. Zhang, et al., “Xiaoyaosan Slows Cancer Progression and Ameliorates Gut Dysbiosis in Mice With Chronic Restraint Stress and Colorectal Cancer Xenografts,” Biomedicine & Pharmacotherapy 132 (2020): 110916.

[51] S. Shao, R. Jia, L. Zhao, et al., “Xiao-Chai-Hu-Tang Ameliorates Tumor Growth in Cancer Comorbid Depressive Symptoms via Modulating Gut Microbiota-Mediated TLR4/MyD88/NF-κB Signaling Pathway,” Phytomedicine 88 (2021): 153606.

[52] Y. Zhou, Y. Feng, R. Cen, et al., “San-Wu-Huang-Qin Decoction Attenuates Tumorigenesis and Mucosal Barrier Impairment in the AOM/DSS Model by Targeting Gut Microbiome,” Phytomedicine 98 (2022): 153966.

[53] Q. Sun, H. Yang, M. Liu, et al., “Berberine Suppresses Colorectal Cancer by Regulation of Hedgehog Signaling Pathway Activity and Gut Microbiota,” Phytomedicine 103 (2022): 154227.

[54] H. Wang, L. Guan, J. Li, M. Lai, and X. Wen, “The Effects of Berberine on the Gut Microbiota in Apc (Min/+) Mice Fed With a High Fat Diet,” Molecules 23, no. 9 (2018): 2298.

[55] M. Wang, Y. Ma, G. Yu, et al., “Integration of Microbiome, Metabolomics and Transcriptome for In-Depth Understanding of Berberine Attenuates AOM/DSS-Induced Colitis-Associated Colorectal Cancer,” Biomedicine & Pharmacotherapy 179 (2024): 117292.

[56] H. Chen, C. Ye, C. Wu, et al., “Berberine Inhibits High Fat Diet-Associated Colorectal Cancer Through Modulation of the Gut Microbiota-Mediated Lysophosphatidylcholine,” International Journal of Biological Sciences 19, no. 7 (2023): 2097-2113.

[57] H. Chen, C. Ye, B. Cai, et al., “Berberine Inhibits Intestinal Carcinogenesis by Suppressing Intestinal Pro-Inflammatory Genes and Oncogenic Factors Through Modulating Gut Microbiota,” BMC Cancer 22, no. 1 (2022): 566.

[58] S. Yan, J. Chang, X. Hao, et al., “Berberine Regulates Short-Chain Fatty Acid Metabolism and Alleviates the Colitis-Associated Colorectal Tumorigenesis Through Remodeling Intestinal Flora,” Phytomedicine 102 (2022): 154217.

[59] H. Chen, F. Zhang, J. Zhang, X. Zhang, Y. Guo, and Q. Yao, “A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based on Microbiome-Metabolomics Analysis,” Frontiers in Immunology 2020 (2020): 11.

[60] X. Wang, A. Peng, and C. Huang, “Suppression of Colon Cancer Growth by Berberine Mediated by the Intestinal Microbiota and the Suppression of DNA Methyltransferases (DNMTs),” Molecular and Cellular Biochemistry 479, no. 8 (2024): 2131-2141.

[61] C. Wu, J. Yang, C. Ye, et al., “Berberine Attenuates 5-Fluorouracil-Induced Intestinal Mucosal Injury by Modulating the Gut Microbiota Without Compromising Its Anti-Tumor Efficacy,” Heliyon 10, no. 14 (2024): e34528.

[62] J. Deng, L. Zhao, X. Yuan, et al., “Pre-Administration of Berberine Exerts Chemopreventive Effects in AOM/DSS-Induced Colitis-Associated Carcinogenesis Mice via Modulating Inflammation and Intestinal Microbiota,” Nutrients 14, no. 4 (2022): 726.

[63] W. Yang, T. Yang, B. Huang, Z. Chen, H. Liu, and C. Huang, “Berberine Improved the Microbiota in Lung Tissue of Colon Cancer and Reversed the Bronchial Epithelial Cell Changes Caused by Cancer Cells,” Heliyon 10, no. 2 (2024): e24405.

[64] K. Cai, X. Y. Cao, F. Chen, et al., “Xianlian Jiedu Decoction Alleviates Colorectal Cancer by Regulating Metabolic Profiles, Intestinal Microbiota and Metabolites,” Phytomedicine 128 (2024): 155385.

[65] H. Zheng, H. Liu, H. Li, et al., “Characterization of Stem Cell Landscape and Identification of Stemness-Relevant Prognostic Gene Signature to Aid Immunotherapy in Colorectal Cancer,” Stem Cell Research & Therapy 13, no. 1 (2022): 244.

[66] Y. Zhu, S. Huang, S. Chen, et al., “SOX2 Promotes Chemoresistance, Cancer Stem Cells Properties, and Epithelial-Mesenchymal Transition by β-Catenin and Beclin1/Autophagy Signaling in Colorectal Cancer,” Cell Death & Disease 12, no. 5 (2021): 449.

[67] F. Wei, T. Zhang, S. C. Deng, et al., “PD-L1 Promotes Colorectal Cancer Stem Cell Expansion by Activating HMGA1-Dependent Signaling Pathways,” Cancer Letters 450 (2019): 1-13.

[68] S. K. Fey, N. Vaquero-Siguero, and R. Jackstadt, “Dark Force Rising: Reawakening and Targeting of Fetal-Like Stem Cells in Colorectal Cancer,” Cell Reports 43, no. 6 (2024): 114270.

[69] Y. Dai, H. Wang, R. Sun, et al., “Modified Shenlingbaizhu Decoction Represses the Pluripotency of Colorectal Cancer Stem Cells by Inhibiting TGF-β Mediated EMT Program,” Phytomedicine 103 (2022): 154234.

[70] L. Wei, P. Chen, Y. Chen, et al., “Pien Tze Huang Suppresses the Stem-Like Side Population in Colorectal Cancer Cells,” Molecular Medicine Reports 9, no. 1 (2014): 261-266.

[71] F. Qi, L. Wei, A. Shen, et al., “Pien Tze Huang Inhibits the Proliferation, and Induces the Apoptosis and Differentiation of Colorectal Cancer Stem Cells via Suppression of the Notch1 Pathway,” Oncology Reports 35, no. 1 (2016): 511-517.

[72] Q. Lu, Z. Zhang, S. Liu, et al., “Inhibition of Stemness and PD-L1 Expression by Pien Tze Huang Enhances T Cell-Mediated Killing of Colorectal Cancer,” Journal of Ethnopharmacology 343 (2025): 119447.

[73] J. M. Shin, E. Lim, Y. S. Cho, and C. W. Nho, “Cancer-Preventive Effect of Phenethyl Isothiocyanate Through Tumor Microenvironment Regulation in a Colorectal Cancer Stem Cell Xenograft Model,” Phytomedicine 84 (2021): 153493.

[74] Y. Chen, Y. Li, X. Q. Wang, et al., “Phenethyl Isothiocyanate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway,” Phytotherapy Research 32, no. 12 (2018): 2447-2455.

[75] Y. J. Huang, C. K. Yang, P. L. Wei, et al., “Ovatodiolide Suppresses Colon Tumorigenesis and Prevents Polarization of M2 Tumor-Associated Macrophages Through YAP Oncogenic Pathways,” Journal of Hematology & Oncology 10, no. 1 (2017): 60.

[76] K. Wang, W. Huang, X. Sang, et al., “Atractylenolide I Inhibits Colorectal Cancer Cell Proliferation by Affecting Metabolism and Stemness via AKT/mTOR Signaling,” Phytomedicine 68 (2020): 153191.

[77] Y. C. Tang, Y. Zhang, J. Zhou, et al., “Ginsenoside Rg3 Targets Cancer Stem Cells and Tumor Angiogenesis to Inhibit Colorectal Cancer Progression In Vivo,” International Journal of Oncology 52, no. 1 (2018): 127-138.

[78] Y. Chen, X. Q. Wang, Q. Zhang, et al., “(−)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway,” Nutrients 9, no. 6 (2017): 572.

[79] A. T. Wu, Y. C. Yeh, Y. J. Huang, N. Mokgautsi, B. Lawal, and T. H. Huang, “Gamma-Mangostin Isolated From garcinia mangostana Suppresses Colon Carcinogenesis and Stemness by Downregulating the GSK3β/β-Catenin/CDK6 Cancer Stem Pathway,” Phytomedicine 95 (2022): 153797.

[80] M. Zhang, X. Li, Q. Zhang, J. Yang, and G. Liu, “Roles of Macrophages on Ulcerative Colitis and Colitis-Associated Colorectal Cancer,” Frontiers in Immunology 14 (2023): 1103617.

[81] H. Wang, T. Tian, and J. Zhang, “Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis,” International Journal of Molecular Sciences 22, no. 16 (2021): 8470.

[82] M. He, J. W. Min, W. L. Kong, X. H. He, J. X. Li, and B. W. Peng, “A Review on the Pharmacological Effects of Vitexin and Isovitexin,” Fitoterapia 115 (2016): 74-85.

[83] Y. Chen, B. Wang, X. Yuan, et al., “Vitexin Prevents Colitis-Associated Carcinogenesis in Mice Through Regulating Macrophage Polarization,” Phytomedicine 83 (2021): 153489.

[84] Y. Chen, J. Liang, S. Chen, et al., “Discovery of Vitexin as a Novel VDR Agonist That Mitigates the Transition From Chronic Intestinal Inflammation to Colorectal Cancer,” Molecular Cancer 23, no. 1 (2024): 196.

[85] H. Liu, S. Yan, R. Yang, et al., “Jiedu Xiaozheng Yin Inhibits the Progression of Colitis Associated Colorectal Cancer by Stimulating Macrophage Polarization Towards an M1 Phenotype via the TLR4 Pathway,” Integrative Cancer Therapies 23 (2024): 15347354241247061.

[86] X. Zuo, H. Lin, Z. Song, B. Yu, and C. Zhao, “Antitumor Activity of Dictamnine Against Colorectal Cancer Through Induction of Ferroptosis and Inhibition of M2 Macrophage Polarization via the MAPK Signaling,” Archives of Biochemistry and Biophysics 758 (2024): 110051.

[87] J. Xun, Z. Hu, M. Wang, et al., “Hydroxygenkwanin Suppresses Peritoneal Metastasis in Colorectal Cancer by Modulating Tumor-Associated Macrophages Polarization,” Chemico-Biological Interactions 396 (2024): 111038.

[88] N. Che, M. Li, X. Liu, C. A. Cui, J. Gong, and Y. Xuan, “Macelignan Prevents Colorectal Cancer Metastasis by Inhibiting M2 Macrophage Polarization,” Phytomedicine 122 (2024): 155144.

[89] Y. Chang, Q. Ou, X. Zhou, et al., “Jianpi Jiedu Decoction Suppresses Colorectal Cancer Growth by Inhibiting M2 Polarization of TAMs Through the Tryptophan Metabolism-AhR Pathway,” International Immunopharmacology 138 (2024): 112610.

[90] A. T. Sougiannis, B. VanderVeen, I. Chatzistamou, et al., “Emodin Reduces Tumor Burden by Diminishing M2-Like Macrophages in Colorectal Cancer,” American Journal of Physiology. Gastrointestinal and Liver Physiology 322, no. 3 (2022): G383-G395, https://doi.org/10.1152/ajpgi.00303.2021.

[91] S. Ge, X. Sun, L. Sang, et al., “Curcumin Inhibits Malignant Behavior of Colorectal Cancer Cells by Regulating M2 Polarization of Tumor-Associated Macrophages and Metastasis Associated in Colon Cancer 1 (MACC1) Expression,” Chemical Biology & Drug Design 102, no. 5 (2023): 1202-1212, https://doi.org/10.1111/cbdd.14330.

[92] Z. Fan, Y. Cui, L. Chen, P. Liu, and W. Duan, “23-Hydroxybetulinic Acid Attenuates 5-Fluorouracil Resistance of Colorectal Cancer by Modulating M2 Macrophage Polarization via STAT6 Signaling,” Cancer Immunology, Immunotherapy 73, no. 5 (2024): 83.

[93] H. Zhang, B. Zhao, H. Wei, H. Zeng, D. Sheng, and Y. Zhang, “Cucurbitacin B Controls M2 Macrophage Polarization to Suppresses Metastasis via Targeting JAK-2/STAT3 Signalling Pathway in Colorectal Cancer,” Journal of Ethnopharmacology 287 (2022): 114915.

[94] Z. Kooshan, L. Cárdenas-Piedra, J. Clements, and J. Batra, “Glycolysis, the Sweet Appetite of the Tumor Microenvironment,” Cancer Letters 600 (2024): 217156.

[95] G. Wang, Y. Z. Wang, Y. Yu, and J. J. Wang, “Inhibitory ASIC2-Mediated Calcineurin/NFAT Against Colorectal Cancer by Triterpenoids Extracted From Rhus chinensis Mill,” Journal of Ethnopharmacology 235 (2019): 255-267.

[96] G. Wang, Y. Z. Wang, Y. Yu, J. J. Wang, P. H. Yin, and K. Xu, “Triterpenoids Extracted From Rhus chinensis Mill Act Against Colorectal Cancer by Inhibiting Enzymes in Glycolysis and Glutaminolysis: Network Analysis and Experimental Validation,” Nutrition and Cancer 72, no. 2 (2020): 293-319.

[97] Y. Li, Y. Wang, Z. Liu, X. Guo, Z. Miao, and S. Ma, “Atractylenolide I Induces Apoptosis and Suppresses Glycolysis by Blocking the JAK2/STAT3 Signaling Pathway in Colorectal Cancer Cells,” Frontiers in Pharmacology 11 (2020): 273.

[98] X. Wei, T. Mao, S. Li, et al., “DT-13 Inhibited the Proliferation of Colorectal Cancer via Glycolytic Metabolism and AMPK/mTOR Signaling Pathway,” Phytomedicine 54 (2019): 120-131.

[99] S. Raina, E. Hübner, E. Samuel, G. Nagel, and H. Fuchs, “DT-13 Attenuates Inflammation by Inhibiting NLRP3-Inflammasome Related Genes in RAW264.7 Macrophages,” Biochemical and Biophysical Research Communications 708 (2024): 149763.

[100] G. Xie, F. Tong, M. Xu, Y. Shu, and Z. Li, “DT-13 Inhibits the Proliferation of Pancreatic Cancer by Inducing Apoptosis via AMPK-mTOR Signaling,” Biochemical and Biophysical Research Communications 695 (2024): 149451.

[101] C. Wang, H. He, G. Liu, et al., “DT-13 Induced Apoptosis and Promoted Differentiation of Acute Myeloid Leukemia Cells by Activating AMPK-KLF2 Pathway,” Pharmacological Research 158 (2020): 104864.

[102] S. Y. Li, J. Shang, X. M. Mao, et al., “Diosgenin Exerts Anti-Tumor Effects Through Inactivation of cAMP/PKA/CREB Signaling Pathway in Colorectal Cancer,” European Journal of Pharmacology 908 (2021): 174370.

[103] S. Chen, M. Nishi, Y. Morine, et al., “Epigallocatechin-3-Gallate Hinders Metabolic Coupling to Suppress Colorectal Cancer Malignancy Through Targeting Aerobic Glycolysis in Cancer-Associated Fibroblasts,” International Journal of Oncology 60, no. 2 (2022): 19.

[104] H. Wu, M. Cui, C. Li, et al., “Kaempferol Reverses Aerobic Glycolysis via miR-339-5p-Mediated PKM Alternative Splicing in Colon Cancer Cells,” Journal of Agricultural and Food Chemistry 69, no. 10 (2021): 3060-3068.

[105] Y. Gan, L. Zhou, R. Wang, et al., “Curcumol Reduces Aerobic Glycolysis and Overcomes Chemoresistance by Inducing Cdh1-Mediated Skp2 Ubiquitination,” American Journal of Chinese Medicine 51, no. 3 (2023): 723-740.

[106] G. Pan, P. Zhang, A. Chen, et al., “Aerobic Glycolysis in Colon Cancer Is Repressed by Naringin via the HIF1Α Pathway,” Journal of Zhejiang University. Science. B 24, no. 3 (2023): 221-231.

[107] X. Sun, L. Zhou, Y. Wang, et al., “Single-Cell Analyses Reveal Cannabidiol Rewires Tumor Microenvironment via Inhibiting Alternative Activation of Macrophage and Synergizes With Anti-PD-1 in Colon Cancer,” Journal of Pharmaceutical Analysis 13, no. 7 (2023): 726-744.

[108] Z. Zhang, Y. Chen, Y. Zheng, et al., “Quxie Capsule Alleviates Colitis-Associated Colorectal Cancer Through Modulating the Gut Microbiota and Suppressing A. fumigatus-Induced Aerobic Glycolysis,” Integrative Cancer Therapies 21 (2022): 15347354221138534.

[109] Q. Zhang, T. Deng, H. Zhang, et al., “Adipocyte-Derived Exosomal MTTP Suppresses Ferroptosis and Promotes Chemoresistance in Colorectal Cancer,” Advanced Science 9, no. 28 (2022): e2203357.

[110] H. Li, K. Yu, H. Hu, et al., “METTL17 Coordinates Ferroptosis and Tumorigenesis by Regulating Mitochondrial Translation in Colorectal Cancer,” Redox Biology 71 (2024): 103087.

[111] R. Singhal, S. R. Mitta, N. K. Das, et al., “HIF-2α Activation Potentiates Oxidative Cell Death in Colorectal Cancers by Increasing Cellular Iron,” Journal of Clinical Investigation 131, no. 12 (2021): e143691, https://doi.org/10.1172/JCI143691.

[112] H. Yan, R. Talty, O. Aladelokun, M. Bosenberg, and C. H. Johnson, “Ferroptosis in Colorectal Cancer: A Future Target?,” British Journal of Cancer 128, no. 8 (2023): 1439-1451.

[113] Y. Wu, D. Pi, S. Zhou, et al., “Ginsenoside Rh3 Induces Pyroptosis and Ferroptosis Through the Stat3/p53/NRF2 Axis in Colorectal Cancer Cells,” Acta Biochimica et Biophysica Sinica 55, no. 4 (2023): 587-600.

[114] S. Luo, G.-J. Tian, F.-X. Yu, and Z.-D. Wen, “A Narrative Review of the Antitumor Studies of Solanine,” Translational Cancer Research 10, no. 3 (2021): 1578-1582.

[115] X. Ma, Y. Li, D. Liang, et al., “Solanine Induces Ferroptosis in Colorectal Cancer Cells Through ALOX12B/ADCY4 Molecular Axis,” Journal of Pharmacy and Pharmacology 76, no. 3 (2024): 224-235.

[116] W. Xin and Y. Zhang, “Curcumin Activates the JNK Signaling Pathway to Promote Ferroptosis in Colon Cancer Cells,” Chemical Biology & Drug Design 103, no. 3 (2024): e14468.

[117] K. Miyazaki, C. Xu, M. Shimada, and A. Goel, “Curcumin and Andrographis Exhibit Anti-Tumor Effects in Colorectal Cancer via Activation of Ferroptosis and Dual Suppression of Glutathione Peroxidase-4 and Ferroptosis Suppressor Protein-1,” Pharmaceuticals (Basel) 16, no. 3 (2023): 383.

[118] M. Chen, A. H. Tan, and J. Li, “Curcumin Represses Colorectal Cancer Cell Proliferation by Triggering Ferroptosis via PI3K/Akt/mTOR Signaling,” Nutrition and Cancer 75, no. 2 (2023): 726-733.

[119] T. Ming, J. Lei, Y. Peng, et al., “Curcumin Suppresses Colorectal Cancer by Induction of Ferroptosis via Regulation of p53 and Solute Carrier Family 7 Member 11/Glutathione/Glutathione Peroxidase 4 Signaling Axis,” Phytotherapy Research 38, no. 8 (2024): 3954-3972.

[120] R. Wei, Y. Zhao, J. Wang, et al., “Tagitinin C Induces Ferroptosis Through PERK-Nrf2-HO-1 Signaling Pathway in Colorectal Cancer Cells,” International Journal of Biological Sciences 17, no. 11 (2021): 2703-2717.

[121] Z. Shen, L. Zhao, S. A. Yoo, et al., “Emodin Induces Ferroptosis in Colorectal Cancer Through NCOA4-Mediated Ferritinophagy and NF-κb Pathway Inactivation,” Apoptosis 29, no. 9-10 (2024): 1810-1823.

[122] J. Q. Lai, L. L. Zhao, C. Hong, et al., “Baicalein Triggers Ferroptosis in Colorectal Cancer Cells via Blocking the JAK2/STAT3/GPX4 Axis,” Acta Pharmacologica Sinica 45, no. 8 (2024): 1715-1726.

[123] J. Geng, Y. Wang, F. Lv, et al., “Coumestrol Facilitates Apoptosis in Colorectal Cancer Cells by Interacting With ZIP8 Protein via the Ferroptosis Pathway,” Journal of Cancer 15, no. 14 (2024): 4656-4667.

[124] Q. Miao, W. Q. Deng, W. Y. Lyu, et al., “Erianin Inhibits the Growth and Metastasis Through Autophagy-Dependent Ferroptosis in KRAS(G13D) Colorectal Cancer,” Free Radical Biology & Medicine 204 (2023): 301-312.

[125] Y. Zheng, L. Li, H. Chen, et al., “Luteolin Exhibits Synergistic Therapeutic Efficacy With Erastin to Induce Ferroptosis in Colon Cancer Cells Through the HIC1-Mediated Inhibition of GPX4 Expression,” Free Radical Biology & Medicine 208 (2023): 530-544.

[126] X. Zhou, J. Kang, L. Zhang, and Y. Cheng, “Osthole Inhibits Malignant Phenotypes and Induces Ferroptosis in KRAS-Mutant Colorectal Cancer Cells via Suppressing AMPK/Akt Signaling,” Cancer Chemotherapy and Pharmacology 92, no. 2 (2023): 119-134.

[127] G. Lian, X. X. Huang, and Y. Zeng, “Puerarin Induces Ferroptosis in Colorectal Cancer Cells via Triggering NCOA4 Upregulation,” Nutrition and Cancer 75, no. 7 (2023): 1571-1578.

[128] P. Vermonden, M. Vancoppenolle, E. Dierge, et al., “Punicic Acid Triggers Ferroptotic Cell Death in Carcinoma Cells,” Nutrients 13, no. 8 (2021): 2751.

[129] J. Y. Huang, T. W. Hsu, Y. R. Chen, and S. H. Kao, “Rosmarinic Acid Potentiates Cytotoxicity of Cisplatin Against Colorectal Cancer Cells by Enhancing Apoptotic and Ferroptosis,” Life 14, no. 8 (2024): 1017, https://doi.org/10.3390/life14081017.

[130] Y. Wu, D. Pi, Y. Chen, Q. Zuo, S. Zhou, and M. Ouyang, “Ginsenoside Rh4 Inhibits Colorectal Cancer Cell Proliferation by Inducing Ferroptosis via Autophagy Activation,” Evidence-Based Complementary and Alternative Medicine 2022 (2022): 6177553.

[131] X. Ma, M. Xu, X. Zhang, et al., “Gambogenic Acid Inhibits Proliferation and Ferroptosis by Targeting the miR-1291/FOXA2 and AMPKα/SLC7A11/GPX4 Axis in Colorectal Cancer,” Cell Biology International 47, no. 11 (2023): 1813-1824.

[132] S. Zhao, Y. Mi, B. Guan, et al., “Tumor-Derived Exosomal miR-934 Induces Macrophage M2 Polarization to Promote Liver Metastasis of Colorectal Cancer,” Journal of Hematology & Oncology 13, no. 1 (2020): 156.

[133] Y. Liang, J. Li, Y. Yuan, et al., “Exosomal miR-106a-5p From Highly Metastatic Colorectal Cancer Cells Drives Liver Metastasis by Inducing Macrophage M2 Polarization in the Tumor Microenvironment,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 281.

[134] Y. Yin, B. Liu, Y. Cao, et al., “Colorectal Cancer-Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD-L1 Expression in Tumor-Associated Macrophages,” Advanced Science 9, no. 9 (2022): 2102620.

[135] A. Prakash, T. Gates, X. Zhao, D. Wangmo, and S. Subramanian, “Tumor-Derived Extracellular Vesicles in the Colorectal Cancer Immune Environment and Immunotherapy,” Pharmacology & Therapeutics 241 (2023): 108332.

[136] R. Li, J. Zhou, X. Wu, et al., “Jianpi Jiedu Recipe Inhibits Colorectal Cancer Liver Metastasis via Regulating ITGBL1-Rich Extracellular Vesicles Mediated Activation of Cancer-Associated Fibroblasts,” Phytomedicine 100 (2022): 154082.

[137] Y. Chen, Q. Yan, Y. Ji, et al., “Unraveling the Serial Glycosylation in the Biosynthesis of Steroidal Saponins in the Medicinal Plant Paris polyphylla and Their Antifungal Action,” Acta Pharmaceutica Sinica B 13, no. 11 (2023): 4638-4654.

[138] H. Hao and A. Sha, “Study on Anti-Fatigue Effects and Mechanisms of Polysaccharide From Paris polyphylla,” Doklady. Biochemistry and Biophysics 516, no. 1 (2024): 58-65.

[139] V. Kshetrimayum, K. D. Chanu, T. Biona, et al., “Paris polyphylla Sm. Characterized Extract Infused Ointment Accelerates Diabetic Wound Healing in In-Vivo Model,” Journal of Ethnopharmacology 331 (2024): 118296.

[140] L. Li, J. Zhang, W. Cheng, F. Di, C. Wang, and Q. An, “Saponins of Paris polyphylla for the Improvement of Acne: Anti-Inflammatory, Antibacterial, Antioxidant and Immunomodulatory Effects,” Molecules 29, no. 8 (2024): 1793.

[141] J. Wang, B. Y. Ni, J. Wang, et al., “Research Progress of Paris polyphylla in the Treatment of Digestive Tract Cancers,” Discover Oncology 15, no. 1 (2024): 31.

[142] L. T. Lin, Y. C. Shi, C. Y. Choong, and C. J. Tai, “The Fruits of Paris polyphylla Inhibit Colorectal Cancer Cell Migration Induced by Fusobacterium nucleatum-Derived Extracellular Vesicles,” Molecules 26, no. 13 (2021): 4081.

[143] C. Gu, H. Lu, and Z. Qian, “Matrine Reduces the Secretion of Exosomal circSLC7A6 From Cancer-Associated Fibroblast to Inhibit Tumorigenesis of Colorectal Cancer by Regulating CXCR5,” Biochemical and Biophysical Research Communications 527, no. 3 (2020): 638-645.

[144] Y. Yang, L. Zhang, X. La, Z. Li, H. Li, and S. Guo, “Salvianolic Acid A Inhibits Tumor-Associated Angiogenesis by Blocking GRP78 Secretion,” Naunyn-Schmiedeberg's Archives of Pharmacology 392, no. 4 (2019): 467-480.

[145] C. Chen, X. Yao, Y. Xu, et al., “Dahuang Zhechong Pill Suppresses Colorectal Cancer Liver Metastasis via Ameliorating Exosomal CCL2 Primed Pre-Metastatic Niche,” Journal of Ethnopharmacology 238 (2019): 111878.

[146] Y. Liu, D. H. Cheng, Z. Y. Su, et al., “Effects of Total Coumarins From Pileostegia tomentella on Exosomal miRNA Expression and Angiogenesis in Colorectal Cancer Cells,” Pharmaceutical Biology 62, no. 1 (2024): 153-161.

[147] J. Chen, S. Duan, Y. Wang, et al., “MYG1 Drives Glycolysis and Colorectal Cancer Development Through Nuclear-Mitochondrial Collaboration,” Nature Communications 15, no. 1 (2024): 4969.

[148] S. Taha-Mehlitz, G. Bianco, M. Coto-Llerena, et al., “Adenylosuccinate Lyase Is Oncogenic in Colorectal Cancer by Causing Mitochondrial Dysfunction and Independent Activation of NRF2 and mTOR-MYC-Axis,” Theranostics 11, no. 9 (2021): 4011-4029.

[149] B. Han, P. Jiang, Z. Li, et al., “Coptisine-Induced Apoptosis in Human Colon Cancer Cells (HCT-116) is Mediated by PI3K/Akt and Mitochondrial-Associated Apoptotic Pathway,” Phytomedicine 48 (2018): 152-160.

[150] L. Zheng, B. Li, A. Yuan, et al., “TFEB Activator Tanshinone IIA and Derivatives Derived From Salvia miltiorrhiza Bge. Attenuate Hepatic Steatosis and Insulin Resistance,” Journal of Ethnopharmacology 335 (2024): 118662.

[151] L. Ma, T. Zhang, R. Wang, et al., “Sodium Tanshinone IIA Sulfonate Protects Primary Cardiomyocytes Against Radiation-Induced Myocardial Injury via the p38 Pathway,” International Heart Journal 65, no. 4 (2024): 730-737.

[152] L. Cao, Z. Qin, T. Yu, et al., “Tanshinone IIA Acts as a Regulator of Lipogenesis to Overcome Osimertinib Acquired Resistance in Lung Cancer,” Biochemical Pharmacology 224 (2024): 116207.

[153] S. Jieensinue, H. Zhu, G. Li, K. Dong, M. Liang, and Y. Li, “Tanshinone IIA Reduces SW837 Colorectal Cancer Cell Viability via the Promotion of Mitochondrial Fission by Activating JNK-Mff Signaling Pathways,” BMC Cell Biology 19, no. 1 (2018): 21.

[154] J. Qian, D. Fang, H. Lu, et al., “Tanshinone IIA Promotes IL2-Mediated SW480 Colorectal Cancer Cell Apoptosis by Triggering INF2-Related Mitochondrial Fission and Activating the Mst1-Hippo Pathway,” Biomedicine & Pharmacotherapy 108 (2018): 1658-1669.

[155] S. Srivastava, J. Dewangan, S. Mishra, et al., “Piperine and Celecoxib Synergistically Inhibit Colon Cancer Cell Proliferation via Modulating Wnt/β-Catenin Signaling Pathway,” Phytomedicine 84 (2021): 153484.

[156] P. B. Yaffe, C. D. Doucette, M. Walsh, and D. W. Hoskin, “Piperine Impairs Cell Cycle Progression and Causes Reactive Oxygen Species-Dependent Apoptosis in Rectal Cancer Cells,” Experimental and Molecular Pathology 94, no. 1 (2013): 109-114.

[157] P. B. Yaffe, M. R. Power Coombs, C. D. Doucette, M. Walsh, and D. W. Hoskin, “Piperine, an Alkaloid From Black Pepper, Inhibits Growth of Human Colon Cancer Cells via G1 Arrest and Apoptosis Triggered by Endoplasmic Reticulum Stress,” Molecular Carcinogenesis 54, no. 10 (2015): 1070-1085.

[158] K. Shaheer, H. M. Somashekarappa, and M. D. Lakshmanan, “Piperine Sensitizes Radiation-Resistant Cancer Cells Towards Radiation and Promotes Intrinsic Pathway of Apoptosis,” Journal of Food Science 85, no. 11 (2020): 4070-4079.

[159] J. K. Tak, J. H. Lee, and J. W. Park, “Resveratrol and Piperine Enhance Radiosensitivity of Tumor Cells,” BMB Reports 45, no. 4 (2012): 242-246.

[160] M. Guéguinou, S. Ibrahim, J. Bourgeais, et al., “Curcumin and NCLX Inhibitors Share Anti-Tumoral Mechanisms in Microsatellite-Instability-Driven Colorectal Cancer,” Cellular and Molecular Life Sciences 79, no. 6 (2022): 284.

[161] C. M. Su, Y. S. Weng, L. Y. Kuan, J. H. Chen, and F. T. Hsu, “Suppression of PKCδ/NF-κB Signaling and Apoptosis Induction Through Extrinsic/Intrinsic Pathways Are Associated Magnolol-Inhibited Tumor Progression in Colorectal Cancer In Vitro and In Vivo,” International Journal of Molecular Sciences 21, no. 10 (2020): 3527.

[162] Y. Fu, Y. Ye, G. Zhu, et al., “Resveratrol Induces Human Colorectal Cancer Cell Apoptosis by Activating the Mitochondrial Pathway via Increasing Reactive Oxygen Species,” Molecular Medicine Reports 23, no. 3 (2021): 1-7.

[163] Y. Qin, Y. Yu, C. Yang, et al., “Atractylenolide I Inhibits NLRP3 Inflammasome Activation in Colitis-Associated Colorectal Cancer via Suppressing Drp1-Mediated Mitochondrial Fission,” Frontiers in Pharmacology 12 (2021): 674340.

[164] Y. Bai, Y. Xiong, Y. Y. Zhang, et al., “Tangeretin Synergizes With 5-Fluorouracil to Induce Autophagy Through MicroRNA-21 in Colorectal Cancer Cells,” American Journal of Chinese Medicine 50, no. 6 (2022): 1681-1701.

[165] L. Long, W. Xiong, F. Lin, et al., “Regulating Lactate-Related Immunometabolism and EMT Reversal for Colorectal Cancer Liver Metastases Using Shikonin Targeted Delivery,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 117.

[166] L. Liang, W. Sun, X. Wei, et al., “Oxymatrine Suppresses Colorectal Cancer Progression by Inhibiting NLRP3 Inflammasome Activation Through Mitophagy Induction In Vitro and In Vivo,” Phytotherapy Research 37, no. 8 (2023): 3342-3362.

[167] J. N. Zeng, J. Y. Tan, and L. Mo, “Naringin Inhibits Colorectal Carcinogenesis by Inhibiting Viability of Colorectal Cancer Cells,” Chinese Journal of Integrative Medicine 29, no. 8 (2023): 707-713.

[168] R. Cai, Y. P. Zhou, Y. H. Li, J. J. Zhang, and Z. W. Hu, “Baicalin Blocks Colon Cancer Cell Cycle and Inhibits Cell Proliferation Through miR-139-3p Upregulation by Targeting CDK16,” American Journal of Chinese Medicine 51, no. 1 (2023): 189-203.

[169] D. Özerkan, “The Determination of Cisplatin and Luteolin Synergistic Effect on Colorectal Cancer Cell Apoptosis and Mitochondrial Dysfunction by Fluorescence Labelling,” Journal of Fluorescence 33, no. 3 (2023): 1217-1225.

[170] A. Al-Menhali, A. Al-Rumaihi, H. Al-Mohammed, et al., “Thymus vulgaris (Thyme) Inhibits Proliferation, Adhesion, Migration, and Invasion of Human Colorectal Cancer Cells,” Journal of Medicinal Food 18, no. 1 (2015): 54-59.

[171] J. Chen, E. Pitmon, and K. Wang, “Microbiome, Inflammation and Colorectal Cancer,” Seminars in Immunology 32 (2017): 43-53.

[172] A. E. V. Quaglio, T. G. Grillo, E. C. S. de Oliveira, L. C. di Stasi, and L. Y. Sassaki, “Gut Microbiota, Inflammatory Bowel Disease and Colorectal Cancer,” World Journal of Gastroenterology 28, no. 30 (2022): 4053-4060.

[173] W. Weng and A. Goel, “Curcumin and Colorectal Cancer: An Update and Current Perspective on This Natural Medicine,” Seminars in Cancer Biology 80 (2022): 73-86.

[174] N. Shivappa, J. Godos, J. R. Hébert, et al., “Dietary Inflammatory Index and Colorectal Cancer Risk-A Meta-Analysis,” Nutrients 9, no. 9 (2017): 1043.

[175] Z. Dal and B. Aru, “The Role of Curcumin on Apoptosis and NLRP3 Inflammasome-Dependent Pyroptosis on Colorectal Cancer In Vitro,” Turkish Journal of Medical Sciences 53, no. 4 (2023): 883-893.

[176] N. Seiwert, J. Fahrer, G. Nagel, J. Frank, D. Behnam, and B. Kaina, “Curcumin Administered as Micellar Solution Suppresses Intestinal Inflammation and Colorectal Carcinogenesis,” Nutrition and Cancer 73, no. 4 (2021): 686-693.

[177] J. Sun, Z. Zhao, J. Lu, et al., “The Tumor Microenvironment Mediates the HIF-1α/PD-L1 Pathway to Promote Immune Escape in Colorectal Cancer,” International Journal of Molecular Sciences 25, no. 7 (2024): 3735.

[178] A. I. Ghoneim, “Effects of Curcumin on Ethanol-Induced Hepatocyte Necrosis and Apoptosis: Implication of Lipid Peroxidation and Cytochrome c,” Naunyn-Schmiedeberg's Archives of Pharmacology 379, no. 1 (2009): 47-60.

[179] Y. Jiao, J. Wilkinson, X. Di, et al., “Curcumin, a Cancer Chemopreventive and Chemotherapeutic Agent, Is a Biologically Active Iron Chelator,” Blood 113, no. 2 (2009): 462-469, https://doi.org/10.1182/blood-2008-05-155952.

[180] Y. Wang, C. Zhang, S. Zhang, et al., “Kanglaite Sensitizes Colorectal Cancer Cells to Taxol via NF-κΒ Inhibition and Connexin 43 Upregulation,” Scientific Reports 7, no. 1 (2017): 1280.

[181] G. Shi, X. Zheng, S. Zhang, et al., “Kanglaite Inhibits EMT Caused by TNF-α via NF-κΒ Inhibition in Colorectal Cancer Cells,” Oncotarget 9, no. 6 (2018): 6771-6779.

[182] H. Sui, L. H. Zhou, Y. L. Zhang, et al., “Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-κB Pathway in Colorectal Cancer,” Journal of Cellular Biochemistry 117, no. 6 (2016): 1471-1481.

[183] L. C. Zhao, J. Li, K. Liao, et al., “Evodiamine Induces Apoptosis and Inhibits Migration of HCT-116 Human Colorectal Cancer Cells,” International Journal of Molecular Sciences 16, no. 11 (2015): 27411-27421.

[184] Y. Zhang, Y. Zhang, Y. Zhao, et al., “Protection Against Ulcerative Colitis and Colorectal Cancer by Evodiamine via Anti-Inflammatory Effects,” Molecular Medicine Reports 25, no. 5 (2022): 188.

[185] M. Wang, B. Zhou, W. Cong, et al., “Amelioration of AOM/DSS-Induced Murine Colitis-Associated Cancer by Evodiamine Intervention Is Primarily Associated With Gut Microbiota-Metabolism-Inflammatory Signaling Axis,” Frontiers in Pharmacology 12 (2021): 797605.

[186] Y. Lu, K. Dong, M. Yang, and J. Liu, “Network Pharmacology-Based Strategy to Investigate the Bioactive Ingredients and Molecular Mechanism of Evodia Rutaecarpa in Colorectal Cancer,” BMC Complementary Medicine and Therapies 23, no. 1 (2023): 433.

[187] P. Zhou, X. P. Li, R. Jiang, et al., “Evodiamine Inhibits Migration and Invasion by Sirt1-Mediated Post-Translational Modulations in Colorectal Cancer,” Anti-Cancer Drugs 30, no. 6 (2019): 611-617.

[188] S. Zeng, L. Tan, Q. Sun, et al., “Suppression of Colitis-Associated Colorectal Cancer by Scutellarin Through Inhibiting Hedgehog Signaling Pathway Activity,” Phytomedicine 98 (2022): 153972.

[189] S. Zeng, L. Chen, Q. Sun, et al., “Scutellarin Ameliorates Colitis-Associated Colorectal Cancer by Suppressing Wnt/β-Catenin Signaling Cascade,” European Journal of Pharmacology 906 (2021): 174253.

[190] J. Ruan, H. Li, M. Lu, et al., “Bioactive Triterpenes of Jujube in the Prevention of Colorectal Cancer and Their Molecular Mechanism Research,” Phytomedicine 110 (2023): 154639.

[191] B. A. Yousef, H. M. Hassan, L. Y. Zhang, and Z. Z. Jiang, “Pristimerin Exhibits In Vitro and In Vivo Anticancer Activities Through Inhibition of Nuclear Factor-кB Signaling Pathway in Colorectal Cancer Cells,” Phytomedicine 40 (2018): 140-147.

[192] B. A. Yousef, M. Guerram, H. M. Hassan, A. M. Hamdi, L. Y. Zhang, and Z. Z. Jiang, “Pristimerin Demonstrates Anticancer Potential in Colorectal Cancer Cells by Inducing G1 Phase Arrest and Apoptosis and Suppressing Various Pro-Survival Signaling Proteins,” Oncology Reports 35, no. 2 (2016): 1091-1100.

[193] J. H. Park and J. K. Kim, “Pristimerin, a Naturally Occurring Triterpenoid, Attenuates Tumorigenesis in Experimental Colitis-Associated Colon Cancer,” Phytomedicine 42 (2018): 164-171.

[194] Z. Yu and W. Li, “Induction of Apoptosis by Puerarin in Colon Cancer HT-29 Cells,” Cancer Letters 238, no. 1 (2006): 53-60.

[195] J. Luo, J. Qu, R. Yang, et al., “Phytochemicals Mediate the Expression and Activity of OCTN2 as Activators of the PPARγ/RXRα Pathway,” Frontiers in Pharmacology 7 (2016): 189.

[196] J. Li, C. Guo, X. Lu, and W. Tan, “Anti-Colorectal Cancer Biotargets and Biological Mechanisms of Puerarin: Study of Molecular Networks,” European Journal of Pharmacology 858 (2019): 172483.

[197] Y. Wang, Y. Ma, Y. Zheng, et al., “In Vitro and In Vivo Anticancer Activity of a Novel Puerarin Nanosuspension Against Colon Cancer, With High Efficacy and Low Toxicity,” International Journal of Pharmaceutics 441, no. 1-2 (2013): 728-735.

[198] X. Q. Deng, H. B. Zhang, G. F. Wang, et al., “Colon-Specific Microspheres Loaded With Puerarin Reduce Tumorigenesis and Metastasis in Colitis-Associated Colorectal Cancer,” International Journal of Pharmaceutics 570 (2019): 118644.

[199] W. Li, S. M. Saud, M. R. Young, N. H. Colburn, and B. Hua, “Cryptotanshinone, a Stat3 Inhibitor, Suppresses Colorectal Cancer Proliferation and Growth In Vitro,” Molecular and Cellular Biochemistry 406, no. 1-2 (2015): 63-73.

[200] Y. S. Su, M. Z. Kuo, Y. T. Kuo, et al., “Diterpenoid Anthraquinones as Chemopreventive Agents Altered microRNA and Transcriptome Expressions in Cancer Cells,” Biomedicine & Pharmacotherapy 136 (2021): 111260.

[201] H. Vundavilli, A. Datta, C. Sima, J. Hua, R. Lopes, and M. Bittner, “Targeting Oncogenic Mutations in Colorectal Cancer Using Cryptotanshinone,” PLoS One 16, no. 2 (2021): e0247190.

[202] L. Zhang, C. Chen, J. Duanmu, et al., “Cryptotanshinone Inhibits the Growth and Invasion of Colon Cancer by Suppressing Inflammation and Tumor Angiogenesis Through Modulating MMP/TIMP System, PI3K/Akt/mTOR Signaling and HIF-1α Nuclear Translocation,” International Immunopharmacology 65 (2018): 429-437.

[203] D. Y. Lee, M. Y. Song, and E. H. Kim, “Role of Oxidative Stress and Nrf2/KEAP1 Signaling in Colorectal Cancer: Mechanisms and Therapeutic Perspectives With Phytochemicals,” Antioxidants 10, no. 5 (2021): 743, https://doi.org/10.3390/antiox10050743.

[204] A. Bardelčíková, J. Šoltys, and J. Mojžiš, “Oxidative Stress, Inflammation and Colorectal Cancer: An Overview,” Antioxidants 12, no. 4 (2023): 901, https://doi.org/10.3390/antiox12040901.

[205] A. Deorukhkar, N. Ahuja, A. L. Mercado, et al., “Zerumbone Increases Oxidative Stress in a Thiol-Dependent ROS-Independent Manner to Increase DNA Damage and Sensitize Colorectal Cancer Cells to Radiation,” Cancer Medicine 4, no. 2 (2015): 278-292.

[206] R. Dehghan, R. Najafi, F. Azizi Jalilian, et al., “A Promising Effect of Zerumbone With Improved Anti-Tumor-Promoting Inflammation Activity of miR-34a in Colorectal Cancer Cell Lines,” Molecular Biology Reports 48, no. 1 (2021): 203-218.

[207] H. W. Cho, K. J. Rhee, and Y. B. Eom, “Zerumbone Restores Gut Microbiota Composition in ETBF Colonized AOM/DSS Mice,” Journal of Microbiology and Biotechnology 30, no. 11 (2020): 1640-1650.

[208] N. Hosseini, A. Khoshnazar, M. Saidijam, et al., “Zerumbone Suppresses Human Colorectal Cancer Invasion and Metastasis via Modulation of FAk/PI3k/NFκB-uPA Pathway,” Nutrition and Cancer 71, no. 1 (2019): 159-171.

[209] Z. Radaei, A. Zamani, R. Najafi, et al., “Promising Effects of Zerumbone on the Regulation of Tumor-Promoting Cytokines Induced by TNF-α-Activated Fibroblasts,” Current Medical Science 40, no. 6 (2020): 1075-1084.

[210] F. Memari, F. Mirzavi, M. Jalili-Nik, A. R. Afshari, A. Ghorbani, and M. Soukhtanloo, “Tumor-Inhibitory Effects of Zerumbone Against HT-29 Human Colorectal Cancer Cells,” International Journal of Toxicology 41, no. 5 (2022): 402-411.

[211] S. Yodkeeree, B. Sung, P. Limtrakul, and B. B. Aggarwal, “Zerumbone Enhances TRAIL-Induced Apoptosis Through the Induction of Death Receptors in Human Colon Cancer Cells: Evidence for an Essential Role of Reactive Oxygen Species,” Cancer Research 69, no. 16 (2009): 6581-6589.

[212] S. Hwang, M. Jo, J. E. Hong, C. O. Park, C. G. Lee, and K. J. Rhee, “Protective Effects of Zerumbone on Colonic Tumorigenesis in Enterotoxigenic Bacteroides fragilis (ETBF)-Colonized AOM/DSS BALB/c Mice,” International Journal of Molecular Sciences 21, no. 3 (2020): 857.

[213] T. Sithara, B. P. Dhanya, K. B. Arun, et al., “Zerumbone, a Cyclic Sesquiterpene From Zingiber zerumbet Induces Apoptosis, Cell Cycle Arrest, and Antimigratory Effects in SW480 Colorectal Cancer Cells,” Journal of Agricultural and Food Chemistry 66, no. 3 (2018): 602-612, https://doi.org/10.1021/acs.jafc.7b04472.

[214] Y. Yu, D. Chen, T. Wu, et al., “Dihydroartemisinin Enhances the Anti-Tumor Activity of Oxaliplatin in Colorectal Cancer Cells by Altering PRDX2-Reactive Oxygen Species-Mediated Multiple Signaling Pathways,” Phytomedicine 98 (2022): 153932.

[215] Z. Yao, A. Bhandari, Y. Wang, et al., “Dihydroartemisinin Potentiates Antitumor Activity of 5-Fluorouracil Against a Resistant Colorectal Cancer Cell Line,” Biochemical and Biophysical Research Communications 501, no. 3 (2018): 636-642.

[216] Z. Wang, X. Sun, Y. Feng, et al., “Dihydromyricetin Reverses MRP2-Induced Multidrug Resistance by Preventing NF-κB-Nrf2 Signaling in Colorectal Cancer Cell,” Phytomedicine 82 (2021): 153414.

[217] J. Liang, J. Wu, F. Wang, P. Zhang, and X. Zhang, “Semaphoring 4D Is Required for the Induction of Antioxidant Stress and Anti-Inflammatory Effects of Dihydromyricetin in Colon Cancer,” International Immunopharmacology 67 (2019): 220-230.

[218] I. Khan, S. Mahfooz, M. Saeed, I. Ahmad, and I. A. Ansari, “Andrographolide Inhibits Proliferation of Colon Cancer SW-480 Cells via Downregulating Notch Signaling Pathway,” Anti-Cancer Agents in Medicinal Chemistry 21, no. 4 (2021): 487-497.

[219] I. Khan, S. Mahfooz, and I. A. Ansari, “Antiproliferative and Apoptotic Properties of Andrographolide Against Human Colon Cancer DLD1 Cell Line,” Endocrine, Metabolic & Immune Disorders Drug Targets 20, no. 6 (2020): 930-942.

[220] I. Khan, F. Khan, A. Farooqui, and I. A. Ansari, “Andrographolide Exhibits Anticancer Potential Against Human Colon Cancer Cells by Inducing Cell Cycle Arrest and Programmed Cell Death via Augmentation of Intracellular Reactive Oxygen Species Level,” Nutrition and Cancer 70, no. 5 (2018): 787-803.

[221] I. Khan, S. Mahfooz, M. Faisal, A. A. Alatar, and I. A. Ansari, “Andrographolide Induces Apoptosis and Cell Cycle Arrest Through Inhibition of Aberrant Hedgehog Signaling Pathway in Colon Cancer Cells,” Nutrition and Cancer 73, no. 11-12 (2021): 2428-2446.

[222] A. Banerjee, V. Banerjee, S. Czinn, and T. Blanchard, “Increased Reactive Oxygen Species Levels Cause ER Stress and Cytotoxicity in Andrographolide Treated Colon Cancer Cells,” Oncotarget 8, no. 16 (2017): 26142-26153.

[223] N. Sharda, T. Ikuse, E. Hill, et al., “Impact of Andrographolide and Melatonin Combinatorial Drug Therapy on Metastatic Colon Cancer Cells and Organoids,” Clinical Medicine Insights: Oncology 15 (2021): 11795549211012672.

[224] H. Hong, W. Cao, Q. Wang, C. Liu, and C. Huang, “Synergistic Antitumor Effect of Andrographolide and Cisplatin Through ROS-Mediated ER Stress and STAT3 Inhibition in Colon Cancer,” Medical Oncology 39, no. 5 (2022): 101.

[225] X. X. Chen, S. Khyeam, Z. J. Zhang, and K. Y. Zhang, “Granatin B and Punicalagin From Chinese Herbal Medicine Pomegranate Peels Elicit Reactive Oxygen Species-Mediated Apoptosis and Cell Cycle Arrest in Colorectal Cancer Cells,” Phytomedicine 97 (2022): 153923.

[226] A. H. Kwok, Y. Wang, and W. S. Ho, “Cytotoxic and Pro-Oxidative Effects of Imperata cylindrica Aerial Part Ethyl Acetate Extract in Colorectal Cancer In Vitro,” Phytomedicine 23, no. 5 (2016): 558-565, https://doi.org/10.1016/j.phymed.2016.02.015.

[227] Y. Wang, Q. Tang, S. Jiang, M. Li, and X. Wang, “Anti-Colorectal Cancer Activity of Macrostemonoside A Mediated by Reactive Oxygen Species,” Biochemical and Biophysical Research Communications 441, no. 4 (2013): 825-830.

[228] C. X. Wang, L. H. Chen, H. B. Zhuang, et al., “Auriculasin Enhances ROS Generation to Regulate Colorectal Cancer Cell Apoptosis, Ferroptosis, Oxeiptosis, Invasion and Colony Formation,” Biochemical and Biophysical Research Communications 587 (2022): 99-106.

[229] O. Cheraghi, G. Dehghan, M. Mahdavi, et al., “Potent Anti-Angiogenic and Cytotoxic Effect of Conferone on Human Colorectal Adenocarcinoma HT-29 Cells,” Phytomedicine 23, no. 4 (2016): 398-405.

[230] Q. Zhao, J. Zhong, Y. Bi, et al., “Gambogenic Acid Induces Noxa-Mediated Apoptosis in Colorectal Cancer Through ROS-Dependent Activation of IRE1α/JNK,” Phytomedicine 78 (2020): 153306.

[231] Y. M. Zheng, J. Z. Shen, Y. Wang, A. X. Lu, and W. S. Ho, “Anti-Oxidant and Anti-Cancer Activities of Angelica dahurica Extract via Induction of Apoptosis in Colon Cancer Cells,” Phytomedicine 23, no. 11 (2016): 1267-1274.

[232] J. Liang, C. Yang, P. Li, et al., “Astragaloside IV Inhibits AOM/DSS-Induced Colitis-Associated Tumorigenesis via Activation of PPARγ Signaling in Mice,” Phytomedicine 121 (2023): 155116.

[233] X. Wang, S. M. Saud, X. Zhang, W. Li, and B. Hua, “Protective Effect of Shaoyao Decoction Against Colorectal Cancer via the Keap1-Nrf2-ARE Signaling Pathway,” Journal of Ethnopharmacology 241 (2019): 111981.

[234] X. Wang, S. M. Saud, F. Wang, et al., “Protective Effect of ShaoYao Decoction on Colitis-Associated Colorectal Cancer by Inducing Nrf2 Signaling Pathway,” Journal of Ethnopharmacology 252 (2020): 112600.

[235] H. Li, Z. Ye, G. Zheng, and Z. Su, “Polysaccharides Targeting Autophagy to Alleviate Metabolic Syndrome,” International Journal of Biological Macromolecules 283, no. Pt 1 (2024): 137393.

[236] Z. Zhang, Y. Zhao, Y. Wang, Y. Zhao, and J. Guo, “Autophagy/Ferroptosis in Colorectal Cancer: Carcinogenic View and Nanoparticle-Mediated Cell Death Regulation,” Environmental Research 238, no. Pt 2 (2023): 117006.

[237] S. N. Devenport, R. Singhal, M. D. Radyk, et al., “Colorectal Cancer Cells Utilize Autophagy to Maintain Mitochondrial Metabolism for Cell Proliferation Under Nutrient Stress,” JCI Insight 6, no. 14 (2021): e138835.

[238] Y. Xuan, S. Zhao, X. Xiao, L. Xiang, and H. C. Zheng, “Inhibition of Chaperone-Mediated Autophagy Reduces Tumor Growth and Metastasis and Promotes Drug Sensitivity in Colorectal Cancer,” Molecular Medicine Reports 23, no. 5 (2021): 360.

[239] F. Burada, E. R. Nicoli, M. E. Ciurea, D. C. Uscatu, M. Ioana, and D. I. Gheonea, “Autophagy in Colorectal Cancer: An Important Switch From Physiology to Pathology,” World Journal of Gastrointestinal Oncology 7, no. 11 (2015): 271-284.

[240] Y. Wu, J. Yao, J. Xie, et al., “The Role of Autophagy in Colitis-Associated Colorectal Cancer,” Signal Transduction and Targeted Therapy 3, no. 1 (2018): 31.

[241] K. Athamneh, H. E. Hasasna, H. A. Samri, et al., “Rhus coriaria Increases Protein Ubiquitination, Proteasomal Degradation and Triggers Non-Canonical Beclin-1-Independent Autophagy and Apoptotic Cell Death in Colon Cancer Cells,” Scientific Reports 7, no. 1 (2017): 11633.

[242] K. Hamze, R. H. Abdallah, N. K. Younis, et al., “2-Nucleobase-Substituted 4,6-Diaminotriazine Analogs: Synthesis and Anti-Cancer Activity in 5-Fluorouracil-Sensitive and Resistant Colorectal Cancer Cells,” Current Medicinal Chemistry 30, no. 26 (2023): 3032-3049.

[243] Z. N. Nizami, M. Al Azzani, S. Khaldi, et al., “Rhus coriaria (Sumac) Induces Autophagic Cell Death and Inhibits mTOR, p38MAPK and STAT3 Pathways in 5fluorouracil-Resistant Colorectal Cancer Cells,” Frontiers in Pharmacology 16 (2025): 1542204.

[244] N. Benhalilou, H. Alsamri, A. Alneyadi, et al., “Origanum majorana Ethanolic Extract Promotes Colorectal Cancer Cell Death by Triggering Abortive Autophagy and Activation of the Extrinsic Apoptotic Pathway,” Frontiers in Oncology 2019 (2019): 9.

[245] K. Athamneh, A. Alneyadi, H. Alsamri, et al., “Origanum majorana Essential Oil Triggers p38 MAPK-Mediated Protective Autophagy, Apoptosis, and Caspase-Dependent Cleavage of P70S6K in Colorectal Cancer Cells,” Biomolecules 10, no. 3 (2020): 412.

[246] H. D. Jeon, Y. H. Han, J. G. Mun, et al., “Dehydroevodiamine Inhibits Lung Metastasis by Suppressing Survival and Metastatic Abilities of Colorectal Cancer Cells,” Phytomedicine 96 (2022): 153809.

[247] X. Xiang, Y. Tian, J. Hu, et al., “Fangchinoline Exerts Anticancer Effects on Colorectal Cancer by Inducing Autophagy via Regulation AMPK/mTOR/ULK1 Pathway,” Biochemical Pharmacology 186 (2021): 114475.

[248] Y. Wang, T. Zhao, C. Huang, et al., “Effect and Mechanism of Banxia Xiexin Decoction in Colorectal Cancer: A Network Pharmacology Approach,” Phytomedicine 123 (2024): 155174.

[249] J. Sun, M. Li, T. Lin, et al., “Cell Cycle Arrest Is an Important Mechanism of Action of Compound Kushen Injection in the Prevention of Colorectal Cancer,” Scientific Reports 12, no. 1 (2022): 4384.

[250] R. H. Gong, D. J. Yang, H. Y. Kwan, A. P. Lyu, G. Q. Chen, and Z. X. Bian, “Cell Death Mechanisms Induced by Synergistic Effects of Halofuginone and Artemisinin in Colorectal Cancer Cells,” International Journal of Medical Sciences 19, no. 1 (2022): 175-185.

[251] L. T. Lin, W. C. Uen, C. Y. Choong, et al., “Paris Polyphylla Inhibits Colorectal Cancer Cells via Inducing Autophagy and Enhancing the Efficacy of Chemotherapeutic Drug Doxorubicin,” Molecules 24, no. 11 (2019): 2102.

[252] L. Shang, Y. Wang, J. Li, et al., “Mechanism of Sijunzi Decoction in the Treatment of Colorectal Cancer Based on Network Pharmacology and Experimental Validation,” Journal of Ethnopharmacology 302, no. Pt A (2023): 115876.

[253] X. Zhu, S. Q. Lin, J. Xie, et al., “Biomarkers of Lymph Node Metastasis in Colorectal Cancer: Update,” Frontiers in Oncology 14 (2024): 1409627.

[254] A. Cañellas-Socias, E. Sancho, and E. Batlle, “Mechanisms of Metastatic Colorectal Cancer,” Nature Reviews. Gastroenterology & Hepatology 21, no. 9 (2024): 609-625.

[255] Y. Liu, L. Lu, P. Cheng, et al., “Wogonin Inhibits Colorectal Cancer Proliferation and Epithelial Mesenchymal Transformation by Suppressing Phosphorylation in the AKT Pathway,” American Journal of Chinese Medicine 52, no. 4 (2024): 1155-1172, https://doi.org/10.1142/S0192415X24500460.

[256] G. Feng, L. Zhang, W. Bao, et al., “Gentisic Acid Prevents Colorectal Cancer Metastasis via Blocking GPR81-Mediated DEPDC5 Degradation,” Phytomedicine 129 (2024): 155615.

[257] J. Y. Zhou, C. Wu, Z. Shen, et al., “Yiqi Huayu Jiedu Decoction Inhibits Liver Metastasis of Colorectal Cancer via Enhancing Natural Killer Cells Function,” Journal of Ethnopharmacology 318, no. Pt A (2024): 116915.

[258] J. Wei, Z. Zheng, X. Hou, et al., “Echinacoside Inhibits Colorectal Cancer Metastasis via Modulating the Gut Microbiota and Suppressing the PI3K/AKT Signaling Pathway,” Journal of Ethnopharmacology 318, no. Pt A (2024): 116866.

[259] Q. H. Huang, J. Zhang, W. C. S. Cho, et al., “Brusatol Suppresses the Tumor Growth and Metastasis of Colorectal Cancer via Upregulating ARRDC4 Expression Through Modulating PI3K/YAP1/TAZ Pathway,” Phytomedicine 109 (2023): 154567.

[260] Z. Q. Liang, Y. Bian, J. F. Gu, et al., “Exploring the Anti-Metastatic Effects of Astragalus mongholicus Bunge-Curcuma aromatica Salisb. On Colorectal Cancer: A Network-Based Metabolomics and Pharmacology Approach,” Phytomedicine 114 (2023): 154772.

[261] F. Liu, Y. Liang, R. Sun, et al., “Astragalus mongholicus Bunge and Curcuma aromatica Salisb. Inhibits Liver Metastasis of Colon Cancer by Regulating EMT via the CXCL8/CXCR2 Axis and PI3K/AKT/mTOR Signaling Pathway,” Chinese Medicine 17, no. 1 (2022): 91, https://doi.org/10.1186/s13020-022-00641-4.

[262] F. Hou, W. Li, Q. Shi, et al., “Yi Ai Fang, a Traditional Chinese Herbal Formula, Impacts the Vasculogenic Mimicry Formation of Human Colorectal Cancer Through HIF-1α and Epithelial Mesenchymal Transition,” BMC Complementary and Alternative Medicine 16, no. 1 (2016): 428.

[263] Q. Ji, X. Liu, Z. Han, et al., “Resveratrol Suppresses Epithelial-To-Mesenchymal Transition in Colorectal Cancer Through TGF-β1/Smads Signaling Pathway Mediated Snail/E-Cadherin Expression,” BMC Cancer 15 (2015): 97.

[264] L. Gao, Y. Feng, C. Ge, et al., “Identification of Molecular Anti-Metastasis Mechanisms of Lycorine in Colorectal Cancer by RNA-Seq Analysis,” Phytomedicine 85 (2021): 153530.

[265] Y. Lu, T. Guan, S. Xu, et al., “Asperuloside Inhibited Epithelial-Mesenchymal Transition in Colitis Associated Cancer via Activation of Vitamin D Receptor,” Phytomedicine 101 (2022): 154070.

[266] R. Li, H. Chi, X. Liao, S. Cen, and Y. Zou, “The Glabridin From Huangqin Decoction Prevents the Development of Ulcerative Colitis Into Colitis-Associated Colorectal Cancer by Modulating MMP1/MMP3 Activity,” International Immunopharmacology 135 (2024): 112262.

[267] G. Dai, B. Sun, T. Gong, Z. Pan, Q. Meng, and W. Ju, “Ginsenoside Rb2 Inhibits Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Suppressing TGF-β/Smad Signaling,” Phytomedicine 56 (2019): 126-135.

[268] İ. Taş, J. Han, S. Y. Park, et al., “Physciosporin Suppresses the Proliferation, Motility and Tumourigenesis of Colorectal Cancer Cells,” Phytomedicine 56 (2019): 10-20.

[269] C. H. Chan, Y. H. Deng, B. Y. Peng, et al., “Anti-Colorectal Cancer Effects of Fucoidan Complex-Based Functional Beverage Through Retarding Proliferation, Cell Cycle and Epithelial-Mesenchymal Transition Signaling Pathways,” Integrative Cancer Therapies 22 (2023): 15347354231213613.

[270] K. Lee, S. G. Cho, Y. K. Choi, et al., “Herbal Prescription, Danggui-Sayuk-Ga-Osuyu-Senggang-Tang, Inhibits TNF-α-Induced Epithelial-Mesenchymal Transition in HCT116 Colorectal Cancer Cells,” International Journal of Molecular Medicine 41, no. 1 (2018): 373-380.

[271] Y. Panahi, M. Saberi-Karimian, O. Valizadeh, et al., “Effects of Curcuminoids on Systemic Inflammation and Quality of Life in Patients With Colorectal Cancer Undergoing Chemotherapy: A Randomized Controlled Trial,” Advances in Experimental Medicine and Biology 1328 (2021): 1-9.

[272] Z. Y. He, C. B. Shi, H. Wen, F. L. Li, B. L. Wang, and J. Wang, “Upregulation of p53 Expression in Patients With Colorectal Cancer by Administration of Curcumin,” Cancer Investigation 29, no. 3 (2011): 208-213.

[273] W. T. Chen, T. S. Yang, H. C. Chen, et al., “Effectiveness of a Novel Herbal Agent MB-6 as a Potential Adjunct to 5-Fluoracil-Based Chemotherapy in Colorectal Cancer,” Nutrition Research 34, no. 7 (2014): 585-594, https://doi.org/10.1016/j.nutres.2014.06.010.

[274] G. R. Irving, L. M. Howells, S. Sale, et al., “Prolonged Biologically Active Colonic Tissue Levels of Curcumin Achieved After Oral Administration—A Clinical Pilot Study Including Assessment of Patient Acceptability,” Cancer Prevention Research 6, no. 2 (2013): 119-128, https://doi.org/10.1158/1940-6207.CAPR-12-0281.

[275] R. A. Sharma, S. A. Euden, S. L. Platton, et al., “Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance,” Clinical Cancer Research 10, no. 20 (2004): 6847-6854.

[276] M. I. James, C. Iwuji, G. Irving, et al., “Curcumin Inhibits Cancer Stem Cell Phenotypes in Ex Vivo Models of Colorectal Liver Metastases, and Is Clinically Safe and Tolerable in Combination With FOLFOX Chemotherapy,” Cancer Letters 364, no. 2 (2015): 135-141.

[277] L. M. Howells, C. O. O. Iwuji, G. R. B. Irving, et al., “Curcumin Combined With FOLFOX Chemotherapy Is Safe and Tolerable in Patients With Metastatic Colorectal Cancer in a Randomized Phase IIa Trial,” Journal of Nutrition 149, no. 7 (2019): 1133-1139.

[278] K. R. Patel, V. A. Brown, D. J. Jones, et al., “Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients,” Cancer Research 70, no. 19 (2010): 7392-7399, https://doi.org/10.1158/0008-5472.CAN-10-2027.

[279] L. M. Howells, D. P. Berry, P. J. Elliott, et al., “Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients With Hepatic Metastases—Safety, Pharmacokinetics, and Pharmacodynamics,” Cancer Prevention Research 4, no. 9 (2011): 1419-1425.

[280] Y. X. Chen, Q. Y. Gao, T. H. Zou, et al., “Berberine Versus Placebo for the Prevention of Recurrence of Colorectal Adenoma: A Multicentre, Double-Blinded, Randomised Controlled Study,” Lancet Gastroenterology & Hepatology 5, no. 3 (2020): 267-275.

[281] J. Venkatesan, S. S. Murugan, and G. H. Seong, “Fucoidan-Based Nanoparticles: Preparations and Applications,” International Journal of Biological Macromolecules 217 (2022): 652-667.

[282] H. L. Tsai, Y. S. Yeh, P. J. Chen, et al., “The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study,” Integrative Cancer Therapies 22 (2023): 15347354231187153, https://doi.org/10.1177/15347354231187153.

[283] H. L. Tsai, C. J. Tai, C. W. Huang, F. R. Chang, and J. Y. Wang, “Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial,” Marine Drugs 15, no. 4 (2017): 122.

[284] J. Levin, S. Maaß, M. Schuberth, et al., “Safety and Efficacy of Epigallocatechin Gallate in Multiple System Atrophy (PROMESA): A Randomised, Double-Blind, Placebo-Controlled Trial,” Lancet Neurology 18, no. 8 (2019): 724-735.

[285] H. Hoensch, B. Groh, L. Edler, and W. Kirch, “Prospective Cohort Comparison of Flavonoid Treatment in Patients With Resected Colorectal Cancer to Prevent Recurrence,” World Journal of Gastroenterology 14, no. 14 (2008): 2187-2193.

[286] C. M. Shin, D. H. Lee, A. Y. Seo, et al., “Green Tea Extracts for the Prevention of Metachronous Colorectal Polyps Among Patients Who Underwent Endoscopic Removal of Colorectal Adenomas: A Randomized Clinical Trial,” Clinical Nutrition 37, no. 2 (2018): 452-458.

[287] F. A. Sinicrope, T. R. Viggiano, N. S. Buttar, et al., “Randomized Phase II Trial of Polyphenon E Versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia,” Cancer Prevention Research 14, no. 5 (2021): 573-580.

[288] T. Zhang, Y. Xu, L. Y. Sun, et al., “Efficacy of Quxie Capsule in Metastatic Colorectal Cancer: Long-Term Survival Update of A Double-Blind, Randomized, Placebo Controlled Trial,” Chinese Journal of Integrative Medicine 28, no. 11 (2022): 971-974.

[289] T. Zhang, Y. F. Yang, B. He, D. H. Yi, J. Hao, and D. Zhang, “Efficacy and Safety of Quxie Capsule () in Metastatic Colorectal Cancer: A Double-Blind Randomized Placebo Controlled Trial,” Chinese Journal of Integrative Medicine 24, no. 3 (2018): 171-177.

[290] X. Geng, Z. Wang, L. Feng, et al., “Efficacy and Safety of Xian-Lian-Jie-Du Optimization Decoction as an Adjuvant Treatment for Prevention of Recurrence in Patients With Stage IIIB/IIIC Colon Cancer: Study Protocol for a Multicentre, Randomized Controlled Trial,” BMC Complementary Medicine and Therapies 23, no. 1 (2023): 239.

[291] F. X. Lin, L. F. Tian, C. Y. Lei, C. C. Ding, L. Shi, and S. F. Zhang, “Chinese Medicine for Outcomes in Colorectal Cancer Patients: A Retrospective Clinical Study,” Chinese Journal of Integrative Medicine 23, no. 9 (2017): 648-653.

[292] Z. Wu, X. Fu, H. Jing, et al., “Herbal Medicine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Advanced Colorectal Cancer: A Prospective Randomized Controlled Trial,” Journal of Ethnopharmacology 325 (2024): 117853.

[293] M. Ni, Y. Zhang, Z. Sun, et al., “Efficacy and Safety of Shenbai Granules for Recurrent Colorectal Adenoma: A Multicenter Randomized Controlled Trial,” Phytomedicine 127 (2024): 155496.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.